Cristina I. Caescu

Cristina I. Caescu

Auto-generated profile, based on publicly available information

Cristina I. Caescu

Department of Systems Biology, Columbia University Irving Medical Center, New York, New York

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 October 2009 in Biochemical Journal
Verified
Journal Article
Closed access
PDF file
CCCristina I. Caescu
Cristina I. Caescu
GJGrace R. Jeschke
Grace R. Jeschke
BTBenjamin E. Turk
Benjamin E. Turk
The metalloproteinases TACE [tumour necrosis factor α-converting enzyme; also known as ADAM17 (a disintegrin and metalloproteinase 17)] and ADAM10 are the primary enzymes responsible for catalysing release of membrane-anchored proteins from the cell surface in metazoan organisms. Although the repertoire of protein substrates for these two proteases is partially overlapping, each one appears to target a subset of unique proteins in vivo. The mechanisms by which the two proteases achieve specificity for particular substrates are not completely understood. We have used peptide libraries to define the cleavage site selectivity of TACE and ADAM10. The two proteases have distinct primary sequence requirements at multiple positions surrounding the cleavage site in their substrates, which allowed us to generate peptide substrates that are highly specific for each of these proteases. The major difference between the two protease specificities maps to the P1′ position (immediately downstream of the cleavage site) of the substrate. At this position, TACE is selective for smaller aliphatic residues, whereas ADAM10 can accommodate aromatic amino acids. Using mutagenesis we identified three residues in the S1′ pockets of these enzymes that dramatically influence specificity for both peptide and protein substrates. Our results suggest that substrate selectivity of TACE and ADAM10 can be at least partly rationalized by specific features of their active sites.

19 February 2015 in Blood
Verified
Journal Article
Closed access
PDF file
CCCristina I. Caescu
Cristina I. Caescu
XGXingyi Guo
Xingyi Guo
LTLydia Tesfa
Lydia Tesfa
TBTushar D. Bhagat
Tushar D. Bhagat
AVAmit Verma
Amit Verma
ESE. Richard Stanley
E. Richard Stanley
Macrophage polarization between the M2 (repair, protumorigenic) and M1 (inflammatory) phenotypes is seen as a continuum of states. The detailed transcriptional events and signals downstream of colony-stimulating factor 1 receptor (CSF-1R) that contributes to amplification of the M2 phenotype and suppression of the M1 phenotype are largely unknown. Macrophage CSF-1R pTyr-721 signaling promotes cell motility and enhancement of tumor cell invasion in vitro. Combining analysis of cellular systems for CSF-1R gain of function and loss of function with bioinformatic analysis of the macrophage CSF-1R pTyr-721–regulated transcriptome, we uncovered microRNA-21 (miR-21) as a downstream molecular switch controlling macrophage activation and identified extracellular signal-regulated kinase1/2 and nuclear factor-κB as CSF-1R pTyr-721–regulated signaling nodes. We show that CSF-1R pTyr-721 signaling suppresses the inflammatory phenotype, predominantly by induction of miR-21. Profiling of the miR-21–regulated messenger RNAs revealed that 80% of the CSF-1–regulated canonical miR-21 targets are proinflammatory molecules. Additionally, miR-21 positively regulates M2 marker expression. Moreover, miR-21 feeds back to positively regulate its own expression and to limit CSF-1R–mediated activation of extracellular signal-regulated kinase1/2 and nuclear factor-κB. Consistent with an anti-inflammatory role of miRNA-21, intraperitoneal injection of mice with a miRNA-21 inhibitor increases the recruitment of inflammatory monocytes and enhances the peritoneal monocyte/macrophage response to lipopolysaccharide. These results identify the CSF-1R–regulated miR-21 network that modulates macrophage polarization. Key Points Analysis of CSF-1R pTyr-regulated messenger RNAs identifies novel signaling nodes and networks that can be targeted to modulate macrophage functions. miR-21 is a novel CSF-1R pTyr-721–induced molecule that suppresses the macrophage M1 phenotype and enhances the M2 phenotype.

1 October 2018 in Matrix Biology
Verified
Journal Article
Closed access
FRFrancesco Ramirez
Francesco Ramirez
CCCristina Caescu
Cristina Caescu
EWElisabeth Wondimu
Elisabeth Wondimu
JGJosephine Galatioto
Josephine Galatioto

16 April 2023 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
PMPrabhjot S. Mundi
Prabhjot S. Mundi
FCFilemon Dela Cruz
Filemon Dela Cruz
AGAdina Grunn
Adina Grunn
DDDaniel Diolaiti
Daniel Diolaiti
AMAudrey Mauguen
Audrey Mauguen
ACAndrea Califano
Andrea Califano
Predicting in vivo response to antineoplastics remains an elusive challenge. We performed a first-of-kind evaluation of two transcriptome-based precision cancer medicine methodologies to predict tumor sensitivity to a comprehensive repertoire of clinically relevant oncology drugs, whose mechanism of action we experimentally assessed in cognate cell lines. We enrolled patients with histologically distinct, poor-prognosis malignancies who had progressed on multiple therapies, and developed low-passage, patient-derived xenograft models that were used to validate 35 patient-specific drug predictions. Both OncoTarget, which identifies high-affinity inhibitors of individual master regulator (MR) proteins, and OncoTreat, which identifies drugs that invert the transcriptional activity of hyperconnected MR modules, produced highly significant 30-day disease control rates (68% and 91%, respectively). Moreover, of 18 OncoTreat-predicted drugs, 15 induced the predicted MR-module activity inversion in vivo. Predicted drugs significantly outperformed antineoplastic drugs selected as unpredicted controls, suggesting these methods may substantively complement existing precision cancer medicine approaches, as also illustrated by a case study. Significance: Complementary precision cancer medicine paradigms are needed to broaden the clinical benefit realized through genetic profiling and immunotherapy. In this first-in-class application, we introduce two transcriptome-based tumor-agnostic systems biology tools to predict drug response in vivo. OncoTarget and OncoTreat are scalable for the design of basket and umbrella clinical trials. This article is highlighted in the In This Issue feature, p. 1275

6 June 2019 in JCI Insight
Verified
Journal Article
Open access
PDF file
JHJens Hansen
Jens Hansen
JGJosephine Galatioto
Josephine Galatioto
CCCristina I. Caescu
Cristina I. Caescu
PAPauline ARNAUD
Pauline ARNAUD
RCRhodora C. Calizo
Rhodora C. Calizo
RIRavi Iyengar
Ravi Iyengar
Marfan syndrome (MFS) is associated with mutations in fibrillin-1 that predispose afflicted individuals to progressive thoracic aortic aneurysm (TAA) leading to dissection and rupture of the vessel wall. Here we combined computational and experimental approaches to identify and test FDA-approved drugs that may slow or even halt aneurysm progression. Computational analyses of transcriptomic data derived from the aortas of MFS patients and MFS mice ( Fbn1 mgR/mgR mice) predicted that subcellular pathways associated with reduced muscle contractility are key TAA determinants that could be targeted with the GABA B receptor agonist baclofen. Systemic administration of baclofen to Fbn1 mgR/mgR mice validated our computational prediction by mitigating arterial disease progression at the cellular and physiological levels. Interestingly, baclofen improved muscle contraction–related subcellular pathways by upregulating a different set of genes than those downregulated in the aorta of vehicle-treated Fbn1 mgR/mgR mice. Distinct transcriptomic profiles were also associated with drug-treated MFS and wild-type mice. Thus, systems pharmacology approaches that compare patient- and mouse-derived transcriptomic data for subcellular pathway–based drug repurposing represent an effective strategy to identify potential new treatments of human diseases.

1 October 2004 in Journal of Bacteriology
Verified
Journal Article
Open access
PDF file
CCCristina I. Caescu
Cristina I. Caescu
OVOlivier Vidal
Olivier Vidal
FKFrédÉrIc Krzewinski
FrédÉrIc Krzewinski
VAVlad Artenie
Vlad Artenie
SBStépHane Bouquelet
StépHane Bouquelet
Although the ability of Bifidobacterium spp. to grow on fructose as a unique carbon source has been demonstrated, the enzyme(s) needed to incorporate fructose into a catabolic pathway has hitherto not been defined. This work demonstrates that intracellular fructose is metabolized via the fructose-6-P phosphoketolase pathway and suggests that a fructokinase (Frk; EC 2.7.1.4) is the enzyme that is necessary and sufficient for the assimilation of fructose into this catabolic route in Bifidobacterium longum . The B. longum A10C fructokinase-encoding gene ( frk ) was expressed in Escherichia coli from a pET28 vector with an attached N-terminal histidine tag. The expressed enzyme was purified by affinity chromatography on a Co 2+ -based column, and the pH and temperature optima were determined. A biochemical analysis revealed that Frk displays the same affinity for fructose and ATP ( K m fructose = 0.739 ± 0.18 mM and K m ATP = 0.756 ± 0.08 mM), is highly specific for d -fructose, and is inhibited by an excess of ATP (>12 mM). It was also found that frk is inducible by fructose and is subject to glucose-mediated repression. Consequently, this work presents the first characterization at the molecular and biochemical level of a fructokinase from a gram-positive bacterium that is highly specific for d -fructose.